Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth.

Journal Article (Journal Article)

Although the potent antitumor activity of nitric oxide (NO) supports its promise as an antineoplastic agent, effective and selective delivery and action on tumor and not normal cells remains a limiting factor. Nanoparticle-based delivery of NO has been considered as one approach to overcome these limitations. Therefore, we determined the utility of NO delivery using silica nanoparticles and evaluated their antitumor efficacy against human ovarian tumor and nontumor cells. The NO-releasing nanoparticles exhibited enhanced growth inhibition of ovarian tumor cells when compared to both control nanoparticles and a previously reported small molecule NO donor, PYRRO/NO. In addition, the NO-releasing nanoparticles showed greater inhibition of the anchorage-independent growth of tumor-derived and Ras-transformed ovarian cells. Confocal microscopy analysis revealed that fluorescently labeled NO-releasing nanoparticles entered the cytosol of the cell and localized to late endosomes and lysosomes. Furthermore, we observed a nanoparticle size dependency on efficacy against normal versus transformed ovarian cells. Our study provides the first application of nanoparticle-derived NO as an antitumor therapy and merits future studies examining nanoparticle formulation for in vivo applications.

Full Text

Duke Authors

Cited Authors

  • Stevens, EV; Carpenter, AW; Shin, JH; Liu, J; Der, CJ; Schoenfisch, MH

Published Date

  • June 2010

Published In

Volume / Issue

  • 7 / 3

Start / End Page

  • 775 - 785

PubMed ID

  • 20205473

Pubmed Central ID

  • PMC3569608

Electronic International Standard Serial Number (EISSN)

  • 1543-8392

International Standard Serial Number (ISSN)

  • 1543-8384

Digital Object Identifier (DOI)

  • 10.1021/mp9002865


  • eng